Late breaking at #ACR23: extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms Another six mont
Tweet Content
Late breaking at #ACR23:
extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms
Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3!
ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85
Show on Archive Page
On
Display in Search Results
On
PDQ
Off